|
Tags:
new of 2013 competition
We are thrilled to present the Next Century Innovators Award finalists. Based on your votes, one of these extraordinary innovators will be honored at the 2013 Innovation Forum, and will have the opportunity to apply for a $100,000 grant.
Speedy Delivery: Putting Poorest Patients at the Center of Drug Development
Bringing GPS-based codes to provide unique addresses to slum-dwellers in India
Out of close to 1000 nominations, we’ve selected the first two of three nominees to receive this year’s Next Century Innovators Award. These innovators are forging new pathways, changing the way we deliver services, and improving conditions for the world’s most vulnerable populations.
Discover the work of these remarkable innovators, and how it is improving the future for us all.
Turning the Tide: Engaging the Public and Private Sector to Conserve Watersheds
DIY Challenge: Empowering Youth in Sierra Leone to Invent Their Future
-------------------------------------------------------
other entrants include:
world’s most pressing problems, in exciting and unexpected ways.
results are in http://centennial.rockefellerfoundation.org/innovators?utm_medium=e...
Only 10 percent of the world’s spending on health research is delegated to diseases affecting 90 percent of the world’s population, such as African sleeping sickness, chagas, malaria, pediatric HIV/AIDS and leishmaniasis. Through its patient-centered research and development model, Drugs for Neglected Diseases (DNDi) discovers, develops and distributes new, improved and affordable medicines for illnesses largely unknown by much of the world. DNDi’s collaborative partnerships with governments, research institutions, NGOs, pharmaceutical and biotechnology companies ensure greater research and knowledge sharing that expedites the development processes and allows faster delivery of much needed drugs. DNDi has also developed new drug licensing agreements which put patient access as the priority. DNDi has delivered six new treatments with the goal of producing 11-13 by 2018; 90 percent of people suffering from African sleeping sickness have been treated with DNDi-produced drugs.
Why it’s Innovative: DNDi rallies all relevant actors in drug development around specified goals to “de-link” the cost of R&D from the price of the final product. This has required several innovations—including partnerships between historical adversaries (such as activists and pharmaceutical companies) and the development of licensing agreements that put patient needs first.
Right now, millions of people are suffering from deadly diseases which are, for the most part, unheard of in many parts of the world. Neglected diseases affect the poorest communities across Africa, Asia and Latin America, but since they do not represent a lucrative market for the pharmaceutical industry, little to nothing is invested to develop life-saving treatments. The Drugs for Neglected Diseases initiative (DNDi) delivers new treatments for neglected diseases that afflict millions of the world’s most vulnerable people.
DNDi carries out patient-centered research and development (R&D) to discover and develop affordable medicines for patients suffering from Chagas disease, leishmaniasis, sleeping sickness, malaria, pediatric HIV/AIDS and specific filarial diseases. DNDi’s approach is to establish collaborative partnerships with public sector research institutions, particularly in disease-endemic countries, pharmaceutical and biotechnology companies, academia, non-governmental organizations, and governments worldwide. DNDi manages every phase of the drug development process – from drug discovery to preclinical research to clinical trials to support for large-scale implementation on the ground – and develops new treatments specifically adapted to the needs of patients. Once developed, the treatments are affordable, non-patented, and made available as public goods.
In the late 1990s, Doctors Without Borders/Médecins Sans Frontiéres (MSF) doctors were increasingly frustrated at their inability to treat patients because needed medicines were either unavailable, toxic or did not exist. In response, MSF committed a portion of its 1999 Nobel Peace Prize funds to develop an alternative model of R&D for drugs, and co-founded DNDi in 2003 with 5 public sector research organizations.
The traditional industry business model for pharmaceutical innovation requires consumers to pay high drug prices in order to “recoup” R&D costs. The DNDi model pulls together existing research capacity around well-defined goals in a way that de-links the cost of R&D from the price of the final product.
Innovative partnerships have been required to achieve this. For example, DNDi harnesses the expertise of pharmaceutical companies on terms that will guarantee affordability and access for patients. This has included the negotiation of increasingly favorable licensing agreements with companies that reduce exclusivity, ensure the widest possible geographic research and manufacturing rights, and aim to achieve the lowest possible sustainable price.
DNDi’s approach overcomes intellectual property barriers to innovation and access and promotes more open exchange of scientific knowledge and data than in the traditional industry business model, ultimately avoiding duplication, reducing R&D costs, and speeding up the R&D process for the benefit of patients.
DNDi has delivered 6 new treatments, reaching millions of people.
For example, DNDi has developed a new treatment for African sleeping sickness, a parasitic disease endemic in sub-Saharan Africa that, left untreated, is 100% fatal. Currently, over 90% of people suffering from African sleeping sickness receive a safe and effective combination drug called NECT, developed by DNDi and its partners. NECT is the first improved treatment for sleeping sickness in 25 years and is currently included on the WHO’s Essential Medicines List. Prior to NECT, the most commonly used medication was melarsoprol -- a drug so toxic it killed one in 20 patients.
DNDi’s objectives are to deliver 11 to 13 new treatments to patients suffering from neglected diseases by 2018, to ensure equitable access to these treatments, and to build a robust pipeline of new drug candidates. With six new treatments developed in less than 10 years, DNDi is well on its way to achieving these goals and to bringing the best science to the most neglected.
DNDi is showing that a paradigm shift is possible in which R&D becomes needs-driven rather than profit-driven, and essential-health R&D is considered a global public good. This model could serve as an important example in international policy dialogues, such as the WHO’s exploration of new models to finance and coordinate essential health R&D, including a proposed new global R&D treaty.
interesting choice of grand winner
|
|
|
===================please note most of this column is due to be re-edited we hope to issue a list of yunus top 10 stories but when it comes to solutions matching those challeges there's all to play for as web3 is humanity's last chnace to leap ahead
hottest youth-spring question of our life and times-can online education end youth unemployment for ever ? yes but only if you help map how!
Breaking News to action now!
About Pro-Youth economics at Norman Macrae Foundation online library of norman macrae - The Economist's Unacknowledged Giant -videos 1 2 -fansweb NMFoundation- youth projects - include yunuschoolusa
fullest press reports Grameen Brand Partnership Architecture
exponential impact advisory: the social business youth networks inspired by muhammad yunus -without which millennium goal actions networks would be way behind are worth far more than any individual parts according to Norman Macrae Foundation trilliondollaraudit methodology and charter notespace
Beyond the extraordinary investment of the members bank at Grameen, and the approximate third share its members foundation holds in grameenphone, here is our Unofficial League Table of Most Impactful Social Business Investments around yunus - last update 1 dec 2012
! Grameen Solar
2 Grameen Mobile Nursing nets and college
3 Portfolio of investments linkedin by Japan
4 Portfolio of youth-led networking inventions in US educationsystem tertiar and secondary - transparency note NM Foundation has minor donation/loan interest
5 Investments in Grameen as collaboration brand linked in out of paris- the origin of global social business partnership funds
6 OpenTech investments of Grameen Intel
-------- while not controlled by yunus we see wholeplanetfoundation microcredit investment table and conscious capitalsm movements and hugely important to advancing pro-youth economicsmission of friends of youth and yunus
email chris.macrae@yahoo.co.ukif you have questions or recommendations of entries that should be in this league table
-please read notes about what pro-youth economists mean by superapps being most
© 2024 Created by chris macrae. Powered by